PROCEPT BioRobotics February 2025 © 2025 PROCEPT BioRobotics Corporation. All Rights Reserved. Safe Harbor Statement This presentation and accompanying oral presentation contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including the expected financial results of PROCEPT BioRobotics Corporation (the "Company"). Words such as "anticipates," "believes," "expects," "intends," "projects," "anticipates," and "future" or similar expressions are intend ...

Group 1: Financial Performance - PROCEPT BioRobotics reported a quarterly loss of $0.35 per share, which aligns with the Zacks Consensus Estimate, an improvement from a loss of $0.54 per share a year ago [1] - The company posted revenues of $68.24 million for the quarter ended December 2024, exceeding the Zacks Consensus Estimate by 2.40%, compared to $43.58 million in the same quarter last year [2] - Over the last four quarters, PROCEPT BioRobotics has surpassed consensus EPS estimates three times and topped consensus revenue estimates four times [2][3] Group 2: Stock Performance and Outlook - PROCEPT BioRobotics shares have declined approximately 19.1% since the beginning of the year, contrasting with the S&P 500's gain of 1.7% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.32 on revenues of $66.34 million, and for the current fiscal year, it is -$1.27 on revenues of $315.64 million [7] - The estimate revisions trend for PROCEPT BioRobotics is mixed, resulting in a Zacks Rank 3 (Hold), indicating expected performance in line with the market in the near future [6] Group 3: Industry Context - The Medical - Instruments industry, to which PROCEPT BioRobotics belongs, is currently ranked in the top 32% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]

Revenue Performance - Total revenue for Q4 2024 was $68.2 million, a 57% increase compared to the prior year period[4] - Full year 2024 total revenue reached $224.5 million, a 65% increase from $136.2 million in 2023[11] - Total revenue for the twelve months ended December 31, 2024, was $224.498 million, a 65% increase compared to $136.191 million in 2023[33] - U.S. total revenue for the three months ended December 31, 2024, was $60.389 million, up 50% from $40.269 million in the same period of 2023[33] - U.S. handpiece and consumables revenue for Q4 2024 was $29.3 million, a 36% increase compared to the prior year[10] - Handpieces and other consumables revenue in the U.S. for the twelve months ended December 31, 2024, reached $110.542 million, a significant increase of 73% from $64.051 million in 2023[33] Profitability and Loss - Net loss for Q4 2024 was $18.9 million, an improvement from a loss of $27.5 million in the prior year[7] - PROCEPT BioRobotics Corporation reported a net loss of $80 million for 2025, with an adjusted EBITDA of $(35) million[29] Operating Expenses - Operating expenses for Q4 2024 were $63.4 million, compared to $50.8 million in the prior year, marking a significant increase[6] Gross Margin - Gross margin for Q4 2024 improved to 64%, up from 49% in the prior year period[5] Assets and Liabilities - Total assets increased to $534.017 million in 2024, up from $404.717 million in 2023, representing a growth of approximately 32%[31] - Current assets rose to $481.842 million in 2024, compared to $350.567 million in 2023, marking a 37% increase[31] - Total liabilities increased slightly to $131.797 million in 2024 from $123.965 million in 2023[31] - The company's accumulated deficit increased to $(545.985) million in 2024 from $(454.572) million in 2023[31] - Cash and cash equivalents grew to $333.725 million in 2024, up from $257.222 million in 2023, indicating a 30% increase[31] Future Projections - The company projects total revenue for 2025 to be approximately $320 million, representing a 42% growth over 2024[10] - The company anticipates a depreciation and amortization expense of $6.8 million for 2025[29] Technological Advancements - The company received FDA 510(k) clearance for the HYDROS™ Robotic System in August 2024, marking a significant technological advancement[3] Install Base - The install base of AquaBeam and Hydros Robotic Systems in the U.S. was 505 systems as of December 31, 2024[4]

SAN JOSE, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported financial results for the fourth quarter and year ended December 31, 2024. Recent Highlights Total revenue of approximately $68.2 million for the fourth quarter of 2024, an increase of 57% compared to the prior year periodU.S. system revenue of $27.6 million for the ...

Financial Results Announcement - PROCEPT BioRobotics will report financial results for the fourth quarter of 2024 after market close on February 25, 2025 [1] - A conference call will be hosted by the Company's management at 4:30 p.m. Eastern Time on the same day [1] Conference Presentations - Management will present at the TD Cowen 45th Annual Healthcare Conference on March 4 at 1:10 p.m. Eastern Time [3] - Additionally, management will present at the 2025 Leerink Partners Healthcare Conference on March 11 at 3:00 p.m. Eastern Time [3] Company Overview - PROCEPT BioRobotics focuses on advancing patient care through surgical robotics, specifically in urology [5] - The Company manufactures the AQUABEAM and HYDROS™ Robotic Systems, with the HYDROS system being the only AI-powered technology delivering Aquablation therapy [5] - Aquablation therapy is designed for effective treatment of lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH), affecting approximately 40 million men in the U.S. [5] - The Company has over 150 peer-reviewed publications supporting the clinical advantages of Aquablation therapy [5]

Core Viewpoint - PROCEPT BioRobotics Corporation (PRCT) has received an upgrade to a Zacks Rank 1 (Strong Buy), indicating a positive outlook based on rising earnings estimates, which significantly influence stock prices [1][4][6]. Earnings Estimates and Revisions - The Zacks rating system is centered around the changing earnings picture, tracking the Zacks Consensus Estimate for EPS from sell-side analysts for the current and following years [2]. - Rising earnings estimates for PROCEPT BioRobotics indicate an improvement in the company's underlying business, which is expected to drive stock price appreciation [6][9]. - The company is projected to earn -$1.75 per share for the fiscal year ending December 2024, reflecting a year-over-year change of 21.9% [9]. Zacks Rating System - The Zacks Rank stock-rating system classifies stocks into five groups based on earnings estimates, with Zacks Rank 1 stocks historically generating an average annual return of +25% since 1988 [8]. - The system maintains a balanced distribution of 'buy' and 'sell' ratings, ensuring that only the top 5% of stocks receive a 'Strong Buy' rating, indicating superior earnings estimate revisions [10][11]. Market Implications - The upgrade of PROCEPT BioRobotics to a Zacks Rank 1 positions it among the top 5% of Zacks-covered stocks, suggesting potential for market-beating returns in the near term [11]. - The correlation between earnings estimate revisions and near-term stock movements highlights the importance of tracking these revisions for investment decisions [7].

SAN JOSE, Calif., Nov. 26, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced that members of management will present at the upcoming 36th Annual Piper Sandler Healthcare Conference in New York City. Management is scheduled to present on Wednesday, December 4 at 8:30 a.m. Eastern Time. A live webcast of each event, as well as an archived recording, will ...

Core Insights - PROCEPT BioRobotics Corporation (NASDAQ: PRCT) has seen a stock increase of 20% following recent fundamental updates, now trading at approximately 16 times forward sales and 20 times book value as investors reassess the value of its equity [1] Group 1 - The stock's performance reflects a positive reappraisal by investors regarding the company's equity value [1] - The current trading multiples indicate a strong market interest and potential growth outlook for PROCEPT BioRobotics [1]

Company Overview - PROCEPT BioRobotics Corporation (PRCT) currently holds a Momentum Style Score of A, indicating strong momentum potential [3] - The company has a Zacks Rank of 2 (Buy), suggesting favorable market performance [4] Price Performance - PRCT shares have increased by 34.2% over the past week, while the Zacks Medical - Instruments industry remained flat during the same period [6] - Over the past month, PRCT's price change is 32.49%, significantly outperforming the industry's 2.19% [6] - In the last quarter, PRCT shares rose by 52.15%, and over the past year, they gained 198.93%, compared to the S&P 500's increases of 13.52% and 37.4%, respectively [7] Trading Volume - The average 20-day trading volume for PRCT is 1,193,537 shares, which serves as a bullish indicator when combined with rising stock prices [8] Earnings Outlook - In the past two months, 6 earnings estimates for PRCT have been revised upwards, while none have been revised downwards, leading to an increase in the consensus estimate from -$1.88 to -$1.74 [10] - For the next fiscal year, 5 estimates have moved upwards, with 1 downward revision during the same period [10]

Group 1 - PROCEPT BioRobotics Corporation announced a public offering of 1,923,076 shares of common stock at a price of $91.00 per share, aiming for gross proceeds of approximately $175 million [1] - A selling stockholder has granted underwriters a 30-day option to purchase an additional 288,461 shares at the public offering price [1] - The offering is expected to close on or about October 31, 2024, subject to customary closing conditions [1] Group 2 - BofA Securities, Piper Sandler, and Morgan Stanley are acting as joint book-running managers for the offering [2] - The securities are being offered under an effective shelf registration statement filed with the SEC on August 1, 2023 [2] Group 3 - PROCEPT BioRobotics focuses on developing transformative solutions in urology, including the AQUABEAM® and HYDROS™ Robotic Systems [5] - The HYDROS Robotic System is noted as the only AI-powered robotic technology delivering Aquablation therapy, which is designed for effective treatment of lower urinary tract symptoms due to BPH [5] - BPH affects approximately 40 million men in the United States, highlighting the market potential for PROCEPT BioRobotics' solutions [5]